Skip to main content

Table 2 Characteristics of patients in whom empirical vancomycin was continued inappropriately during the pre-intervention and intervention periodsa

From: Effect of an intervention targeting inappropriate continued empirical parenteral vancomycin use: a quasi-experimental study in a region of high MRSA prevalence

  Pre-intervention period Intervention period P value
No. of prescriptions 303 272  
Male, n (%) 181 (59.7) 163 (59.9) 0.963
Age, median years (IQR) 60 (48–71) 61 (49–72) 0.528
Comorbid condition, n (%)
 Diabetes mellitus 68 (22.4) 53 (19.5) 0.385
 Chronic liver disease 28 (9.2) 27 (9.9) 0.780
 Chronic lung disease 10 (3.3) 1 (0.4) 0.010
 Cerebrovascular disease 10 (3.3) 11 (4.0) 0.635
 Solid malignancy 86 (28.4) 68 (25.0) 0.360
 Hematological malignancy 58 (19.1) 72 (26.5) 0.036
 Connective tissue disease 8 (2.6) 8 (2.9) 0.827
 Azotemia 46 (15.2) 46 (16.9) 0.572
 Neutropenia 61 (20.1) 63 (23.2) 0.378
Suspected site of infection, n (%)    0.214
 Pneumonia 68 (22.4) 50 (18.4)  
 Intraabdominal infection 32 (10.6) 42 (15.4)  
 CNS infection 34 (11.2) 32 (11.8)  
 Skin and soft tissue infection 62 (20.5) 50 (18.4)  
 Cardiovascular infection 2 (0.7) 5 (1.8)  
 Catheter-related infection 25 (8.3) 16 (5.9)  
 Bone and joint infection 31 (10.2) 8 (2.9)  
 Urinary tract infection 5 (1.7) 3 (1.1)  
 Other infection 19 (6.3) 19 (7.0)  
 Unknown 25 (8.3) 47 (17.3)  
Admission department, n (%)    0.303
 Medial ward 165 (54.5) 176 (64.7)  
 Surgical ward 86 (28.4) 46 (16.9)  
 Medical ICU 33 (10.9) 30 (11.0)  
 Surgical ICU 19 (6.3) 20 (7.4)  
30-days mortality, n (%) 53 (17.5) 37 (13.6) 0.200
  1. Abbreviations: CNS central nervous system, ICU intensive care unit
  2. aWhen empirically prescribed vancomycin treatment was continued beyond 96 h without documentation of beta-lactam-resistant gram-positive microorganisms in clinical specimens with significance, the continuation was considered inappropriate